-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca to present updated Phase 1 AURORAS-1 monotherapy data for ERAS-0015 at ENA Symposium

PUBT·09/10/2026 12:05:47
Listen to the news
Erasca to present updated Phase 1 AURORAS-1 monotherapy data for ERAS-0015 at ENA Symposium
  • Erasca flagged updated Phase 1 AURORAS-1 monotherapy results for ERAS-0015 for future presentation at the ENA Symposium on Nov. 20.
  • The company pointed to clinical activity with favorable tolerability in earlier disclosures, positioning the expanded dataset as a key near-term catalyst.
  • Nonclinical combination findings for ERAS-0015 with ERAS-4001 will also be presented, highlighting synergistic effects in KRAS G12X-driven models.
  • Management framed the readouts as supporting plans to move ERAS-0015 toward three potentially registration-enabling trials in pancreatic cancer and lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100800PRIMZONEFULLFEED9824377) on September 10, 2026, and is solely responsible for the information contained therein.